Healthcare Industry News:  liver metastases 

Devices Oncology

 News Release - August 15, 2012

Sirtex Medical Inc. Expands U.S. Operations to Accommodate Increased Demand for SIR-Spheres Microspheres

WOBURN, Mass.--(Healthcare Sales & Marketing Network)--Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (SRX.AX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today expansion of U.S. operations with the placement of additional sales, marketing and functional support staff in Massachusetts and across the country. Sirtex produces SIR-Spheres® microspheres, the only fully FDA-approved microsphere radiation therapy for the treatment of colorectal liver metastases. The expansion follows the announcement of record growth for Sirtex in the U.S. in terms of dose sales for SIR-Spheres microspheres. Product for the U.S. market is currently produced at the company’s manufacturing facilities in Wilmington, Mass.

Sirtex’s expansion is part of the company’s previously announced global growth plan that began in the U.S. in July 2010, with additions in July 2011, and the latest annual installment in 2012.

“Sirtex continues to reach new milestones related to the number of U.S. dose sales, and we look forward to continuing to expand the business and build awareness for SIR-Spheres microspheres so more patients have access to this beneficial cancer treatment,” said Michael Mangano, president of Sirtex Medical Inc. “This latest expansion will allow us to accommodate current and future growth by addressing the increased demand for SIR-Spheres microspheres in treatment centers across the country and effectively reaching more patients diagnosed with colorectal liver tumors.”

For more information visit www.sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres).

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA approval), and the European Union (CE Mark) and additionally supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 400 treatment centers, over 20,000 doses of SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd


Source: Sirtex Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.